GSK at ESMO 2024

GSK will be at the European Society for Medical Oncology (ESMO) Congress 2024. Date: 13 – 17 September Location: Barcelona, Spain

ESMO Gynaecological Cancers Congress 2024: Supporters

GSK is focused on maximising patient survival through transformational medicines. Our goal is to achieve a sustainable flow of new treatments in immuno-oncology ...

GSK at Oncology Medical Congresses 2024

GSK will be at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting and the 2024 European Hematology Association (EHA) Hybrid Congress.

Oncology - Scientific Meetings - GSK US Medical Affairs

ESMO. September 13-17, 2024 | Barcelona, Spain. Oncology. Show Filters. 0 Show Filters. 0 Hide Filters. Clear selected filters. Resource Types (13). Audio ...

ESMO-GYN - Scientific Meetings - GSK US Medical Affairs

Medical Information Page: Oncology ESMO-GYN June 20-22, 2024 | Florence, Italy Resource Types Presentation Deck

ESMO 2024: TIGIT race tightens with first look at GSK/iTeos's TIGIT ...

GSK and iTeos finally provided the first data reveal of their TIGIT inhibitor, belrestotug, in combination with Jemperli (dostarlimab) in the first-line, PD-L1 ...

GSK [46676] ESMO Gyn Symposium_Weblink PDF_A4-V04

The Royal Marsden NHS Foundation Trust,. London, UK. Panel moderator. Chair. ESMO Gynaecological Cancers Congress. 2024 Industry Satellite ...

GSK at ESMO 2024 - LinkedIn

As part of our continued commitment to driving progress for cancer patients, we are pushing the boundaries of science to deliver ...

Optimizing Long-term Patient Outcomes with PARPi Treatment for ...

The information included is for Healthcare Professionals only. For Healthcare Professionals only | PM-GBL-NRP-LBND-240004 July 2024. ESMO 2024 ...

ESMO: GSK's Zejula, Pharma&'s Rubraca-Opdivo combo disappoint

In a rough day for PARP inhibitors in ovarian cancer, GSK's Zejula didn't deliver a life extension benefit in the final analysis of a phase 3 trial.

ESMO: iTeos-GSK's TIGIT star shows meaningful improvement

By Gabrielle Masson Sep 14, 2024 2:30am. ESMO 2024 iTeos Therapeutics GSK TIGIT. Share. galaxy, galaxies iTeos Therapeutics and GSK are launching their ...

ESMO Congress 2024: Companies

GSK is focused on maximising patient survival through transformational medicines. Our goal is to achieve a sustainable flow of new treatments in immuno-oncology ...

ESMO Congress 2024 PPTX Template - iTeos Therapeutics

Medicine 2024;103:e36861; 4. GSK, Jemperli SmPC (2024) available from https://www.ema.europa.eu/en/documents/product-information/jemperli ...

ESMO 2024 preview – TIGIT gets its late-breaker - Oncology Pipeline

ESMO will take place in Barcelona, Spain, on 13-17 September 2024.

Conferences - GSK

GSK was at the European Society Medical Oncology (ESMO) Congress 2024. Read ... GSKPro for healthcare professionals · GSK study register · Supplier website ...

ESMO 2024 Preview: Bispecifics and TIGITs Among the ... - BioSpace

Graybosch is looking forward to late-breaker presentations on iTeos Therapeutics and GSK's anti-TIGIT therapy EOS-448 and BMS's lymphocyte- ...

ESMO Immuno-Oncology Congress 2024: Exhibitor Profiles

GSK is committed to maximising patient survival through transformational medicines. GSK's oncology pipeline is focused on immuno-oncology, tumour cell targeting ...

Interim analysis of GALAXIES Lung-201: Phase II ... - OncologyPRO

ESMO Congress 2024. Proffered paper session: NSCLC metastatic. LBA52 - Interim ... Parkhomenko: Financial Interests, Personal, Full or part-time Employment: GSK; ...

ESMO Congress 2024 On site Exhibitor List

GSK. Guardant Health. Harvest Integrated Research Organization (HiRO). Helsinn Group. ICON. Companies. 336. 427. 619. 431f. 428. 638. 516. 536. 347. 501. 502.

ESMO Congress 2024: Industry Participation

ESMO 2024, the world's premier congress in medical oncology! ... The congress will attract an international community of experts, across disciplines and all ...